Pure Extracts Technologies Corp. (CSE:PULL)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

Pure Extracts Agrees to Licensing deal with Taste-T, LLC the US manufacturer of Fireball Cannabis Gummies

Vancouver, BC – February 16, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTCPK: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to announce its licensing deal with U.S. based Taste-T, LLC (“Taste-T”).

 

Taste-T utilizes a proprietary manufacturing system to produce and package branded cannabis gummies and sells them in multiple U.S. states including Nevada, Massachusetts, Michigan and Oklahoma. Their famous products include Margarita Chill and Fireball Cinnamon and come in unique blister packaging.

 

Pure Extracts has signed an agreement with exclusive rights for Canada and first rights to other countries around the world.  Included in the agreement is the delivery to Pure Extracts’ British Columbia facility of one of Taste-T’s custom built gummie manufacturing machines, certified to Canadian standards. Pure Extracts will be selling these products in a Health Canada compliant format in licensed dispensaries throughout Canada under their ‘Pure Chews’ brand of edible products.

 

Pure Extracts’ CEO, Ben Nikolaevsky, remarked, “Taste-T’s gummy line up represents a great opportunity for our Company to leverage one of the few U.S. cannabis products that can legitimately be call a ‘brand’. And of course, as a Canadian company, Pure Extracts is ideally suited to export this product to numerous countries around the world.”

 

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

 

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

 

For further information please contact Empire Communications Group at (604) 343-2724.

 

ON BEHALF OF THE BOARD

Ben Nikolaevsky
Ben Nikolaevsky
CEO and Director

 

The CSE has neither approved nor disapproved the contents of this press release.

 

This information release contains certain forward-looking information, including about the timing and completion of the Private Placement, the proposed use of proceeds of the Private Placement, the filing of a preliminary short form prospectus, the receipt of CSE approval and the listing of the Warrants. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

SOURCE:  Pure Extracts Technologies Corp.

Pure Extracts Commences Build-Out of Facility in Preparation for Mushroom Extraction and Dealers License

Vancouver, BC – December 16, 2020 – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has begun to build-out the 4th unit in its facility for the extraction of mushrooms and to commence research and development of psilocybin under a Dealers Licence.

 

The Company is preparing an application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA), which provides, among other things, the framework for legal access to controlled substances, and the control and regulation of production, distribution and sale of psilocybin

 

Under this framework, a company is required to obtain a licence issued by Health Canada in order to conduct various activities with controlled substances. Licence holders are responsible for compliance with the CDSA and its Regulations as well as compliance with other applicable federal, provincial and territorial legislation and municipal by-laws. The issued licence dictates activities, conditions, and restrictions for the licence holder depending on licence permissions.

 

A Dealer’s Licence could allow for the following activities:

 

  • Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
  • Research and manufacture of controlled substances such as psilocybin and psilocin
  • Business to business sale of controlled substances, including by export
  • Sale of controlled substance via pharmacies

 

Pure Extracts CEO, Ben Nikolaevsky, remarked, “As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be building-out our facility for our move into the controlled substances world of psychedelics. It’s great to have space adjacent to our cutting-edge facility which is built to Health Canada standards and to know that this space will also have the same high standards of construction that Pure Extracts prides itself on.”

 

Having the ability to do extraction research and development into psychedelic compounds such as psilocybin and psilocin will prepare Pure Extracts to work with partners such as medical doctors, pharmaceutical company and pharmacies as clinical trials lead to the legalization of psychedelics and the advancement of micro-dosing in the near future.

 

Submission of the Company’s Dealer’s License application is subject to compliance with applicable securities laws, including any necessary approvals by the CSE.

 

About Pure Extracts (CSE: PULL) (XFRA: A2QJAJ)

 

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

 

For further information please contact Empire Communications Group at (604) 343-2724.

 

ON BEHALF OF THE BOARD

Ben Nikolaevsky
Ben Nikolaevsky
CEO and Director

 

The CSE has neither approved nor disapproved the contents of this press release.

 

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. The Company is in the preliminary stages of preparing a Dealer’s License application and there is no certainty on the timing of such application, or that the Company will ultimately be successful is obtaining a Dealer’s License. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

 

Source:  Pure Extracts Technologies Corp.

Pure Extracts Applauds Health Canada SAP for Psilocybin-Assisted Psychotherapy Inclusion

Special Access Programme Review Considered a Milestone Event Toward Mainstream Acceptance

 

Vancouver, BC – December 14, 2020 – Pure Extracts Technologies Corp . (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, and the rapidly emerging functional mushroom sector, is pleased to support Health Canada’s proposed intent to revise the Special Access Programme (SAP) and related regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments. The intended SAP revision, announced on December 11th, could lead to important new medical applications, particularly in the complex and growing mental health sector.

 

Health Canada’s announcement could act as a milestone achievement driving advanced research initiatives forward. This includes several ongoing clinical trials that consistently indicate breakthrough therapy potential of psilocybin-assisted psychotherapy for a number of mental health patients suffering from conditions where conventional therapies have failed or have proven unsuitable.

 

The proposed SAP update emphasizes the strategic importance of Pure Extracts engagement of a globally recognized operations, compliance, and regulatory consulting firm to advise on the Company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA). The CDSA and its Regulations provide the framework for legal access to controlled substances, and the control and regulation of production, distribution, and sale. One of Health Canada’s responsibilities is to provide the licensing and oversight framework for the legal production of controlled substances.

 

Upon acceptance, a Dealer’s License could allow Pure Extracts to engage in the following activities:

 

>> Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
>> Research and manufacture of controlled substances such as psilocybin and psilocin
>> Business to business sale of controlled substances, including by export
Sale of controlled substance via pharmacies

 

Expanding upon the strategic importance of the SAP review, Pure Extracts recently announced a collaboration with Dr. Alexander MacGregor as a key scientific advisor to the Company. Pure Extracts and Dr. MacGregor are collaborating on the development and research of optimum psilocybin extraction methodologies in preparation to service the needs of the rapidly advancing growth and demand in the sector.

 

As previously noted, Dr. MacGregor is the Dean of Faculty, a distinguished Professor of Biopharmaceutics, and current President of the Toronto Institute of Pharmaceutical Technology (TIPT) – North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which holds a Health Canada Drug Establishment License, a Cannabis Drug License, and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA). Transpharm Canada conducts clinical trials, drug development and is licensed to possess psychedelic drug compounds.

 

Pure Extracts CEO Ben Nikolaevsky states, “The Special Access Programme may prove to be the tipping point and fundamental milestone event that eventually transforms an entire segment of the medical community’s outlook towards the treatment of mental health conditions. With greater and more open access to trials, researchers can move towards larger and more comprehensive studies eventually including thousands of patient candidates. Through multiple large-scale studies, we see great promise in determining treatment safety, efficacy, and desired outcomes. Our research suggests a broad spectrum of products encompassing multiple formulations will be required to service demand across potentially intensive therapies through to microdosing protocols. Exact formulations and high-quality products will be required, and that is fundamentally the sort of work we understand and excel at. Here at Pure Extracts, we believe in the future of the mushroom-based drug development sector and are committed to building value based on the growing number of positive indicators for future success.”

 

About Pure Extracts (CSE: PULL) (XFRA: A2QJAJ)

 

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/ .

 

For further information please contact Empire Communications Group at (604) 343-2724.

 

ON BEHALF OF THE BOARD
“ Ben Nikolaevsky ”
Ben Nikolaevsky
CEO and Director

 

The CSE has neither approved nor disapproved the contents of this press release.

 

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. The Company is in the preliminary stages of preparing a Dealer’s License application and there is no certainty on the timing of such application, or that the Company will ultimately be successful is obtaining a Dealer’s License. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations .

 

Source:  Pure Extracts Technologies Corp .

About Pure Extracts Technologies


Pure Extracts (CSE: PULL) is positioned for growth in the commercial cannabis and psychedelics sector based on extensive extraction and production experience. With a team of qualified experts in the space and cutting-edge CO² and ethanol extraction technology, the Company is set up for long-term strategic distribution and product innovation.

 

The Company’s facility located in Pemberton, BC is built for EU-GMP certification (allowing for international sales) and aims to produce high quality, high purity formulations on a commercial scale. Solvent free, scalable production allows the Company to develop and deliver white-label formulations to service contract sales.

 

Pure Extracts – our brand is our promise.

 

PRODUCT PURITY. PRODUCT QUALITY.

 

Pure Extracts uses CO2 extraction technology to derive full spectrum oil from cannabis biomass. We are an emerging leader in the extraction space offering only the purest quality oil.

 

Extraction Formulation Brand Development

 

Our approach is multi-faceted and comprehensive as it includes elements that allow for future growth & expansion, scalability and increased productivity.

 

Extraction is our business.

 

Our Vitalis CO² Extraction system produces Full Spectrum Oil (FSO) which is one of the purest and highest quality oils.

 

We are aiming for a capacity of over 100,000 kg of biomass per year with a technique that has been tried and tested through our teams’ industry experience.

 

Industry leading quality assurance

 

Pure Extracts is equipped to offer a variety of different product formulations in the near future, each with specific functionalities.

 

Product formulations will be of optimal quality, composed of Pure Extracts’ oils and blends of natural ingredients.

 

Pure Extract’s long-term product expansion plan will be strategically rolled out in three phases.
For more information about our Quality Development Plan download our investor presentation here.

 

The Extract Market in Canada is still in its infancy

 

A very limited number of companies are focused on oil extraction. This provides an opportunity for a company with proven ability and perspective to leverage long term experience in the field.

 

Brand Development is unique to our business model and makes Pure Extracts the only sector-specialized extractor to enter the Canadian Market with a comprehensive Brand Expansion Plan.

 

The Functional Products & Emerging Psychedelic Compounds markets represent outstanding growth opportunities in uncrowded sectors

 

Alongside our Cannabis and CBD business lines, Pure Extracts is ideally positioned to rapidly develop and commercialize functional wellness products and psychedelic medicinal products to serve the R&D and drug discovery growth drivers of this exciting new sector.

 

WHITE LABEL PRODUCTION

 

As part of its core services, Pure Extracts provides white label solutions from custom formulating oils to sourcing both cannabis and hemp biomass to designing and manufacturing consumer-ready packaging for its customers. Pure Extracts is the one-stop solution for companies licensed to sell specialized oil extracts and for CPG brands seeking licensed manufacturing partners.

 

TOLL PROCESSING

 

Pure Extracts offers specialty processing to Canadian Licensed Producers. Through contract processing, Pure Extracts will provide high quality oil to companies to either re-market or sell under their own brand.

 

Source:  https://pureextractscorp.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty nine hundred dollars for Pure Extracts Technologies Corp.  current news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Pure Extracts Technologies Corp.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!